(Q37691691)

22 August 2017

1 reference

title

Ki67 in breast cancer: prognostic and predictive potential (English)

1 reference

22 August 2017

1 reference

Rinat Yerushalmi

1

1 reference

22 August 2017

Ryan Woods

2

1 reference

22 August 2017

Peter M Ravdin

3

1 reference

22 August 2017

Malcolm M Hayes

4

1 reference

22 August 2017

Karen A Gelmon

5

1 reference

22 August 2017

language of work or name

1 reference

1 February 2010

1 reference

Lancet Oncology Commission

22 August 2017

published in

1 reference

22 August 2017

volume

11

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

174-183

1 reference

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Assignment of the human Ki-67 gene (MKI67)to 10q25-qter

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Immunoelectron-microscopic localization of a proliferation-associated antigen Ki-67 in MCF-7 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Monoclonal antibodies Ki-S3 and Ki-S5 yield new data on the 'Ki-67' proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Chromophore-assisted light inactivation of pKi-67 leads to inhibition of ribosomal RNA synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Measuring proliferation in breast cancer: practicalities and applications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Measurement of proliferation marker Ki67 in breast tumour FNAs using laser scanning cytometry in comparison to conventional immunocytochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Tissue microarrays for comparing molecular features with proliferation activity in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Difference in Ki67 and Thymidylate Synthase Expression in Primary Tumour Compared with Metastatic Nodes in Breast Cancer Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Steroid receptors and proliferation in the human breast.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Expression of ER, Ki-67 and cylinD1 in the pre-cancerous breast of Chinese patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Reduction in proliferation with six months of letrozole in women on hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Sebaceous carcinoma of the breast: case report and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Comparison of core needle biopsy and surgical specimens in malignant breast lesions regarding histological features and hormone receptor expression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Quantitative growth fraction evaluation with MIB1 and Ki67 antibodies in breast carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

HER-2 and topoisomerase II as predictors of response to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Letrozole in the neoadjuvant setting: the P024 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970262-1

7 January 2021

10.1016/S1470-2045(09)70262-1

Identifiers

DOI

1 reference

22 August 2017

1 reference